CR6968A - Un nuevo compuesto derivado de la triptamina y sus analogos. - Google Patents

Un nuevo compuesto derivado de la triptamina y sus analogos.

Info

Publication number
CR6968A
CR6968A CR6968A CR6968A CR6968A CR 6968 A CR6968 A CR 6968A CR 6968 A CR6968 A CR 6968A CR 6968 A CR6968 A CR 6968A CR 6968 A CR6968 A CR 6968A
Authority
CR
Costa Rica
Prior art keywords
triptamine
analogs
new compound
compound derived
compositions
Prior art date
Application number
CR6968A
Other languages
English (en)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of CR6968A publication Critical patent/CR6968A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a nuevas triptaminas sustituidas y derivados relacionados, como asi tambien composiciones farmaceuticas formuladas con los mismos. estos compuestos , composiciones y sus sales pueden ser usados en la fabricacion de medicamentos para interactuar con el sistema melatoninergico. Estos compuestos y estas composiciones pueden ser usados para tratar diferentes tipos de condiciones medicas, tales como trastornos del sistema nervioso central y psiquiatricos, trastornos cronobiologicos, condiciones neoplasticas y condiciones asocieadas con la senescencia.
CR6968A 2000-10-03 2003-05-02 Un nuevo compuesto derivado de la triptamina y sus analogos. CR6968A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL138825A IL138825A (en) 2000-10-03 2000-10-03 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
PCT/IL2001/000898 WO2002028347A2 (en) 2000-10-03 2001-09-25 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them

Publications (1)

Publication Number Publication Date
CR6968A true CR6968A (es) 2004-02-25

Family

ID=11074694

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6968A CR6968A (es) 2000-10-03 2003-05-02 Un nuevo compuesto derivado de la triptamina y sus analogos.

Country Status (40)

Country Link
US (2) US6780884B2 (es)
EP (1) EP1331935B1 (es)
JP (1) JP2004533986A (es)
KR (1) KR100855385B1 (es)
CN (1) CN100518735C (es)
AR (1) AR035587A1 (es)
AT (1) ATE409474T1 (es)
AU (1) AU9416201A (es)
BG (1) BG107759A (es)
BR (1) BR0114464A (es)
CA (1) CA2423628C (es)
CL (1) CL2001002303A1 (es)
CR (1) CR6968A (es)
CY (1) CY1110417T1 (es)
CZ (1) CZ301098B6 (es)
DE (1) DE60136003D1 (es)
DK (1) DK1331935T3 (es)
EA (1) EA005918B1 (es)
EE (1) EE05192B1 (es)
ES (1) ES2315307T3 (es)
GT (1) GT200100197A (es)
HK (1) HK1074163A1 (es)
HN (1) HN2001000218A (es)
HU (1) HU227163B1 (es)
IL (1) IL138825A (es)
IS (1) IS2607B (es)
MX (1) MXPA03002612A (es)
NO (1) NO20031396L (es)
NZ (1) NZ525587A (es)
PA (1) PA8529801A1 (es)
PE (1) PE20020411A1 (es)
PL (1) PL365679A1 (es)
PT (1) PT1331935E (es)
SI (1) SI1331935T1 (es)
SK (1) SK4042003A3 (es)
TW (1) TWI270544B (es)
UA (1) UA75091C2 (es)
UY (1) UY26946A1 (es)
WO (1) WO2002028347A2 (es)
ZA (1) ZA200303113B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1694323A4 (en) * 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc METHOD FOR TREATING A DISEASE
CA2556753C (en) * 2004-02-20 2014-11-25 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
KR20080031266A (ko) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Ｐａｒｐ 조절제 및 암의 치료
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
AU2008271911B2 (en) 2007-06-29 2014-08-07 Phovitreal Pty Ltd Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
JP5746615B2 (ja) * 2008-05-13 2015-07-08 エール ユニヴァーシティ 癌細胞への抗体の動員のためのキメラ小分子
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
EP2713883B1 (en) 2011-05-31 2024-07-10 Clarencew Pty Ltd. Methods for preventing and treating motor-related neurological conditions
CA2853729A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
RU2750989C2 (ru) * 2016-03-14 2021-07-07 Сомалоджик, Инк. Композиции и способы синтеза 5-(n-защищенного триптаминкарбоксамида)-2'-дезоксиуридинфосфорамидита для включения в нуклеиновую кислоту

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6310085B1 (en) * 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders

Also Published As

Publication number Publication date
HN2001000218A (es) 2002-05-09
BG107759A (bg) 2004-01-30
HUP0302616A2 (hu) 2003-11-28
GT200100197A (es) 2002-05-08
BR0114464A (pt) 2004-01-20
CZ2003940A3 (cs) 2003-10-15
SI1331935T1 (sl) 2009-04-30
UA75091C2 (en) 2006-03-15
IL138825A (en) 2006-06-11
EE05192B1 (et) 2009-08-17
NO20031396D0 (no) 2003-03-27
CN1582147A (zh) 2005-02-16
EE200300135A (et) 2003-08-15
EP1331935A4 (en) 2004-12-01
CZ301098B6 (cs) 2009-11-04
NO20031396L (no) 2003-03-27
AR035587A1 (es) 2004-06-16
CL2001002303A1 (es) 2010-06-25
EA005918B1 (ru) 2005-06-30
IS2607B (is) 2010-04-15
MXPA03002612A (es) 2004-04-02
CY1110417T1 (el) 2015-04-29
HU227163B1 (en) 2010-09-28
EA200300436A1 (ru) 2003-10-30
US20050020664A1 (en) 2005-01-27
US6780884B2 (en) 2004-08-24
WO2002028347A2 (en) 2002-04-11
ZA200303113B (en) 2004-07-23
PE20020411A1 (es) 2002-05-16
SK4042003A3 (en) 2003-09-11
IL138825A0 (en) 2001-10-31
HK1074163A1 (en) 2005-11-04
US20040029950A1 (en) 2004-02-12
AU9416201A (en) 2002-04-15
EP1331935B1 (en) 2008-10-01
DK1331935T3 (da) 2009-02-02
CN100518735C (zh) 2009-07-29
JP2004533986A (ja) 2004-11-11
UY26946A1 (es) 2001-11-30
CA2423628A1 (en) 2002-04-11
NZ525587A (en) 2005-03-24
DE60136003D1 (de) 2008-11-13
TWI270544B (en) 2007-01-11
EP1331935A2 (en) 2003-08-06
ATE409474T1 (de) 2008-10-15
PL365679A1 (en) 2005-01-10
WO2002028347A3 (en) 2002-07-04
KR20030051689A (ko) 2003-06-25
PT1331935E (pt) 2009-01-19
KR100855385B1 (ko) 2008-09-04
PA8529801A1 (es) 2002-12-30
CA2423628C (en) 2011-04-26
IS6752A (is) 2003-03-21
ES2315307T3 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
PA8615701A1 (es) Derivados de dihidrobenzofuranilo alcanamina y metodos para su uso.
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
SV2002000022A (es) Inhibidores de recanalizacion de la monoamida para el tratamiento de los desordenes del sistema nervioso central ref. pc10434
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
PA8504801A1 (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
GT200900280A (es) Derivados de 2 piridin carboxamida como moduladores de los canales de sodio
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY29673A1 (es) Derivados sustituidos de 6-(4-clorofenil) tieno (3,2,d)- pirimidin- 4(3h)-ona y (1,2,3,)-triazin-4-(3h)-ona,composiciones farmaceuticas conteniéndolos, procesosde peparación y aplicaciones.
AR058807A1 (es) 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
CL2004000848A1 (es) Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
UY28374A1 (es) Agentes terapéuticos
PA8845601A1 (es) Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1)
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
CR6968A (es) Un nuevo compuesto derivado de la triptamina y sus analogos.
CU20130116A7 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
CR9407A (es) Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia
PA8542601A1 (es) Bifenilcarboxamidas reductoras de lipidos
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
AR008244A1 (es) Compuestos heterociclicos, procedimiento para prepararlos, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos